SEC Form 4 · accession 0001104659-17-043682
Nabriva Therapeutics Legacy plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Crotty
Officer — General Counsel & Corp Secreta
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001703287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Jun 30, 2017 | A | 90,000 | A | — | Jun 30, 2027 | Ordinary Shares | 90,000 | 90,000 | D |
Explanation of responses
- F1The exercise price is $10.48 per share.
- F2This option was granted on June 30, 2017. Vesting will begin on June 30, 2017 and end on June 30, 2021. Twenty-five percent (25%) of the option will vest on June 30, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.